Latest news with #MiniMed780G
Yahoo
31-05-2025
- Business
- Yahoo
Does This Move Make Medtronic Stock a Buy?
Medtronic's diabetes care unit has grown faster than the rest of its business in recent years. However, the company decided to spin off this segment into a stand-alone corporation. Still, Medtronic has several growth avenues and an impeccable dividend program. 10 stocks we like better than Medtronic › Over the past few years, Medtronic (NYSE: MDT) has faced significant challenges, including a pandemic-induced slowdown, relatively slow revenue growth, and economic issues that impacted its financial results. Throughout it all, Medtronic's diabetes care business has consistently been one of its fastest-growing segments. However, the healthcare leader recently announced some news regarding this unit that might surprise some investors. Let's find out more about it and discuss what it means for Medtronic's prospects. Medtronic markets several products within its diabetes care segment. Perhaps its most important line is its insulin pump franchise. One of the latest iterations of this was the MiniMed 780G, which came with several nifty features, including automatic insulin dose corrections. Medtronic also markets continuous glucose monitoring (CGM) systems that allow diabetes patients to keep track of their blood sugar levels, with constant measurements every few minutes. Additionally, it offers insulin pens and a software that collects information from CGM devices, insulin pumps, and smart pens to create reports to inform patients' progress or share with medical professionals. There is considerable room for growth in the diabetes market. Of the half-billion adults worldwide with diabetes, only 1% had access to CGM technology as of the end of 2023. One might think Medtronic would seize the vast untapped opportunity, especially considering its diabetes care unit's faster growth. During the company's fiscal 2025, ended April 25, Medtronic reported revenue of $33.6 billion, up 3.6% compared to the previous fiscal year. The company's diabetes care segment generated $2.8 billion in sales, with year-over-year growth of 10.7%. True, it still makes up a small part of its business, but given the massive worldwide opportunity, it might have eventually become its biggest growth driver if it kept up its much faster growth pace for a long time. However, Medtronic announced that it would spin off its diabetes care unit, which will become a stand-alone, publicly traded corporation within the next 18 months. Medtronic wants to simplify its portfolio and focus its resources on core, high-margin growth opportunities. That's the rationale management gave for the separation. What does it mean for investors? Medtronic would likely struggle to catch up with the leaders in the diabetes care field. Abbott Laboratories and DexCom dominate the CGM market. In the insulin pump niche, Medtronic has had to compete with companies such as Tandem Diabetes Care. Perhaps Medtronic felt it would not be competitive in these and other niches of the diabetes market over the long run, hence its decision to focus on markets where it "has leading core competencies," to borrow the company's phrasing. While Medtronic will lose its fastest-growing segment, its business should remain robust. The company still markets dozens of products across several other areas that generate consistent revenue and profits. In today's challenging environment, investors tend to gravitate toward steady and stable corporations like Medtronic. Furthermore, the healthcare leader recently announced important news. The company is requesting U.S. clearance for its Hugo robotic-assisted surgery (RAS) system in urologic procedures after the device delivered strong clinical trial results. Approval of Medtronic's RAS Hugo system in the U.S. should unlock massive opportunities, given the industry's underpenetration and significant runway for growth. Finally, Medtronic remains an excellent dividend stock, and it recently announced yet another payout hike. The medical device specialist has increased its dividends for 48 consecutive years -- just two more and it will join the exclusive rank of Dividend Kings. Even with the potential impact of tariffs, Medtronic has performed relatively well this year compared to broader equity markets. In the long run, it should be able to mitigate the effects of tariffs, given its diversified business and consistent earnings, which can enable it to shift its manufacturing around. Medtronic remains a top pick for long-term, income-oriented investors despite spinning off its fastest-growing unit. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!* Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom and Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic, long January 2027 $65 calls on DexCom, short January 2026 $85 calls on Medtronic, and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. Does This Move Make Medtronic Stock a Buy? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
21-05-2025
- Business
- Time of India
Medtronic to separate diabetes business into standalone company
Bengaluru: Medical device maker Medtronic said on Wednesday it plans to separate its diabetes business, which houses its insulin pumps and other wearable devices, into a stand-alone company. The new company will be headed by Que Dallara, the current chief of Medtronic's diabetes division , and will house about 8,000 employees and be headquartered in Northridge, California. The diabetes unit has recently struggled after a 2021 warning by regulators about the company's MiniMed 600 insulin pumps. The spin off would allow Medtronic to focus on more profitable businesses such as heart devices , its biggest revenue driver. The spin off is expected to be complete within the next 18 months through a series of capital markets deals, with a preferred path of an initial public offering and subsequent split-off. The separation was first reported by the Wall Street Journal earlier on Wednesday. In 2022, the U.S. Food and Drug Administration flagged a cybersecurity risk for the MiniMed 600 Series insulin pump system, cautioning that the device was susceptible to cyberattacks that could potentially disrupt insulin delivery. The decision to separate the diabetes business follows years of restructuring efforts, which included a delay in the FDA clearance for the MiniMed 780G insulin pump until 2023. Separately, the company posted an adjusted profit of $1.62 per share for the fourth quarter ended April 25, ahead of Wall Street estimates of $1.58 per share, according to LSEG data. Its revenue of $8.93 billion also beat estimates of $8.82 billion, driven by sales of both heart devices and diabetes devices. Shares in the Ireland-based company were up marginally in pre-market trading.
Yahoo
21-05-2025
- Business
- Yahoo
Medtronic Q4 Earnings and Revenues Top, Stock Down in Pre-market
Medtronic plc MDT reported adjusted earnings per share (EPS) of $1.62 for the fourth quarter of fiscal 2025. The bottom line rose 10.9% from the year-ago quarter's figure and beat the Zacks Consensus Estimate by 2.5%. Currency-adjusted EPS for the reported quarter was $1.69. Without certain one-time adjustments — including amortization, restructuring and associated costs, certain litigation charges and acquisition-related costs, among others — GAAP EPS was 82 cents, reflecting a 67.3% improvement from the year-ago quarter's reported figure. Full-year fiscal 2025 adjusted EPS was $5.49, up 5.6% year over year. The figure beat the Zacks Consensus Estimate by 0.5%. Following the announcement today, MDT shares fell 0.4% in the premarket trading. Medtronic's recent decision to spin off its diabetes division into an independent, publicly traded company might have put pressure on the company's share price. Worldwide revenues in the reported quarter grossed $8.93 billion, up 3.9% year over year on a reported basis and 5.4% on an organic basis. The top line surpassed the Zacks Consensus Estimate by 1.1%. Full-year fiscal 2025 worldwide revenues totaled $33.54 billion, up 3.6% year over year. The top line marginally surpassed the Zacks Consensus Estimate by 0.1%. The company reports revenues under four major segments: Cardiovascular, Medical Surgical, Neuroscience and Diabetes. In the fiscal fourth quarter, Cardiovascular revenues increased 7.8% organically to $3.37 billion. Within this, Cardiac Rhythm & Heart Failure sales totaled $1.75 billion, up 10.3% year over year organically. Revenues from Structural Heart & Aortic rose 8.3% organically to $955 million. Coronary & Peripheral Vascular revenues grew 1% organically to $667 million. In the Medical Surgical portfolio, worldwide sales totaled $2.24 billion, up 2% year over year organically. While Surgical & Endoscopy revenues edged up 1.7% organically to $1.73 billion, Acute Care & Monitoring revenues increased 3.1% organically to $508 million. In Neuroscience, worldwide revenues of $2.64 billion were up 3.7% year over year organically. Cranial & Spinal Technologies sales reached $1.35 billion, up 4.4% year over year organically. Specialty Therapies revenues totaled $766 million, down 1.6% year over year organically. Neuromodulation revenues grew 10.2% organically to $524 million. Revenues in the Diabetes group rose 12% organically to $739 million. U.S. revenues grew in high single digits on the continued adoption of the MiniMed 780G automated insulin delivery system, with an increase in the MiniMed 780G installed base and strong CGM (continuous glucose monitoring) attachment rates. International revenues grew in the mid-teens, driven by increasing CGM attachment rates as users upgraded to the Simplera Sync sensor. (See the Zacks Earnings Calendar to stay ahead of market-making news). Gross margin in the reported quarter expanded 19 basis points (bps) to 64.7% despite a 3.4% rise in the cost of revenues. Research and development expenses rose 1.3% year over year to $684 million. Selling, general and administrative expenses fell 1.6% to $2.72 billion. Adjusted operating margin expanded 210 bps year over year to 26.6%. For (full) fiscal 2026, Medtronic projects organic revenue growth of 5%. The organic revenue growth guidance excludes the impact of foreign currency and revenues related to certain businesses reported as Other. Medtronic PLC price-consensus-eps-surprise-chart | Medtronic PLC Quote Including Other revenues and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, fiscal 2026 revenue growth on an adjusted basis is likely to be in the range of 4.8-5.1%. The Zacks Consensus Estimate for fiscal 2026 worldwide revenues is pegged at $35.05 billion, implying 4.6% growth from the year-ago reported figure. Full-year adjusted EPS is expected to be in the range of $5.50-$5.60. The Zacks Consensus Estimate for the year's adjusted earnings is pegged at $5.82 per share. Medtronic exited the fourth quarter of fiscal 2025 with better-than-expected results, wherein both earnings and revenues beat estimates. Neuromodulation delivered an above-market performance, driven by Pain Stim growth, including strong U.S. growth propelled by the continued launch of the Inceptiv spinal cord stimulator. The company's long-term investments in cutting-edge innovation, such as pulsed-field ablation, are beginning to yield results, driving growth in some of the most attractive MedTech markets. Additionally, the expansion of both margins in the quarter is highly encouraging. Medtronic currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are AngioDynamics ANGO, Integer Holdings Corporation ITGR and Phibro Animal Health PAHC. AngioDynamics, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a loss of 13 cents. You can see the complete list of today's Zacks #1 Rank stocks here. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 composite's 10.5%. The company beat on earnings in each of the trailing four quarters, the average surprise being 70.9%. Integer Holdings, sporting a Zacks Rank #1 at present, posted a first-quarter 2025 adjusted EPS of $1.31, which outpaced the Zacks Consensus Estimate by 3.1%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. ITGR has an estimated long-term earnings growth rate of 20.8% compared with the industry's 14.3%. The company's earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 2.8%. Phibro Animal Health, currently carrying a Zacks Rank #2 (Buy), reported a third-quarter fiscal 2025 adjusted EPS of 63 cents, which surpassed the Zacks Consensus Estimate by 21.1%. Revenues of $347.8 million missed the Zacks Consensus Estimate by 0.7%. PAHC has an estimated long-term earnings growth rate of 26% compared with the industry's 15.8%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Los Angeles Times
18-05-2025
- Business
- Los Angeles Times
Bioscience Firms in Southern California Focus on Innovation & Collaboration
Southern California is one of the nation's leading life science hubs, led by the vast cluster of companies in San Diego County that focus on research and development. However, the sector is spread throughout the region with employers such as Amgen in Thousand Oaks and Edwards Lifesciences in Irvine featured among the top companies. New drug developments and delivery systems are some of the leading recent breakthroughs from local companies. Treatments have been created for a wide range of ailments, such as neuromuscular diseases, diabetes, eye disease and cancer, among others. Over the past few months, San Diego-based Avidity Biosciences Inc. reported multiple positive datasets from its three clinical-stage programs in rare muscle diseases. It is preparing for commercialization in anticipation of three potential products that could launch in close succession next year. 'Avidity's mission is to revolutionize the delivery of RNA therapeutics to make a profound difference in the lives of people living with serious rare diseases, many of whom have no or limited treatment options,' said Sarah Boyce, Avidity's chief executive. 'We plan to file our first biologics license application for our DMD44 drug candidate and accelerate commercial preparations for three potential product launches in rapid succession in all three rare neuromuscular diseases.' In Northridge, Medtronic Diabetes received approval from the Food and Drug Administration in April for its Simplera Sync sensor for use with the insulin delivery system MiniMed 780G. The new sensor is a disposable all-in-one that requires no fingerpricks. It plans a limited launch of the product this fall. 'We're committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day,' said Que Dallara, president of Medtronic Diabetes, in a statement. Aliso Viejo-based Glaukos Corp. reported positive clinical updates in January for its iDose TR sustained-release procedural pharmaceutical platform. The company focuses on treatments of chronic eye diseases such as glaucoma, cataracts and diseases that impact the cornea and retina. In February, it followed up on their previous announcement with FDA acceptance of its new drug application for Epioxa, a therapy for keratoconus, which affects the cornea, and set an October goal for the FDA to review the treatment. In January, Agoura Hills-based A2 Biotherapeutics closed an $80-million Series C funding round that will be used for three clinical development programs of its precision cell therapies. Investors include The Column Group and Samsara BioCapital. 'We are excited by the initial clinical data from our lead programs, which we believe validates our proprietary logic-gate technology approach to solid tumor cancers,' said Jim Robinson, CEO of A2 Bio, in a statement. Other companies are expanding through collaboration. San Diego-based Amprion announced a collaboration with Mayo Clinic Laboratories to expand access to Amprion's SAAmplify test across the United States. The partnership is expected to improve diagnostic accuracy for neurodegenerative diseases. 'Amprion has developed early and accurate diagnostic tools for a range of neurodegenerative diseases, including Parkinson's, Lewy Body Dementia, and Multiple System Atrophy. Through this partnership, Amprion and Mayo are able to provide patients, physicians and families with one of the most comprehensive diagnostic offerings available,' said Russ Lebovitz, Amprion chief executive.
Yahoo
19-04-2025
- Business
- Yahoo
Medtronic (NYSE:MDT) Gains FDA Approval for Advanced Insulin Sensor in 2025
Medtronic recently announced the FDA approval for its Simplera Sync sensor, enhancing the MiniMed 780G system with significant technological advancements. Over the past week, Medtronic's share price remained flat, moving in line with broader market trends, which saw a 1.1% decline. Despite the positive product-related news, the share price was likely influenced by market dynamics, as the overall market context played a substantial role in Medtronic's performance. While the company's innovation could have supported its stock, it did little to counteract the prevailing trends affecting the market as a whole. Buy, Hold or Sell Medtronic? View our complete analysis and fair value estimate and you decide. Find companies with promising cash flow potential yet trading below their fair value. The recent FDA approval for Medtronic's Simplera Sync sensor, a significant enhancement to the MiniMed 780G system, highlights Medtronic's commitment to technological advancements. While the approval has yet to translate into immediate share price growth, it aligns well with Medtronic's long-term strategy of expanding its Cardiac Ablation Solutions and other innovative platforms such as the Hugo robotic system. Over the past year, Medtronic's total return, which includes both share price and dividends, increased by 7.44%. This occurs as the company continues to focus on emerging markets like India and innovations such as the Renal Denervation technique, positioning itself for future revenue increases. Comparatively, the company matched the US Medical Equipment industry, which returned 4.5% over one year and underperformed the broader US market return of 5.9% over the same period. The market's muted response to the FDA approval may have been influenced by current market dynamics, but the potential for higher future revenue and earnings remains. Analyst forecasts suggest revenue growth to US$38.2 billion by 2028, with earnings reaching US$6.1 billion, while Medtronic's shares trade at a discount compared to the analyst price target of US$96.83, with the current share price around 15% lower at US$82.7. If future clinical and regulatory milestones are met, the resulting revenue impact could help Medtronic achieve the forecasted growth and justify the analyst consensus price target. However, competitive pressures and regulatory dynamics remain variables to monitor closely. Examine Medtronic's past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:MDT. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
